Eric Brown is a Professor and Chair of the Department of Biochemistry and Biomedical Sciences at McMaster University in Hamilton, Canada and the Director of the McMaster High Throughput Screening Laboratory.  Dr. Brown’s research is in phenotypic and physical studies of core physiology of bacteria.  He has received a variety of awards including a Canada Research Chair in Chemical Biology and the Merck Frosst Prize.  Dr. Brown has served on the advisory boards of a number of biotech companies as well as national and international societies and associations.  He has served as President of the Canadian Society of Biochemistry, Molecular and Cellular Biology and as an Editor of the Journal of Biological Chemistry and has authored some 75 papers in peer-reviewed scientific journals.

Xianghai Chen, MSc, MD, is interested in drug development and the clinical application of therapeutics in the fields of genomics, stem cell biology and immunology. Dr. Chen has published 11 peer-reviewed papers, was a cofounder of Haiyu Biotech (China) and served as its scientific director until 2009, and is one of organizers of the International Association for Biochip Application.

Jack Gauldie, Ph.D., is University Professor in the Department of Pathology and Molecular Medicine and Director of the Institute for Molecular Medicine and Health at McMaster University. His research interests include the molecular basis of chronic inflammation, gene therapy, drug discovery and the development of immune responses. Among his many distinctions, Dr. Gauldie is a Fellow of the Royal Society of Canada and has been awarded the Medal of Honour by the Canadian Medical Association. Dr. Gauldie has published 315 peer-reviewed papers, and is a member of the Editorial Board of leading journals including the Journal of Clinical Investigation and Journal of Immunology.

Peter N. Green, Ph.D., F.I. Biol., is Curator of the National Collection of Industrial Food and Marine Bacteria (NCIMB), the largest public service collection of environmental bacteria in the United Kingdom. He has 35 years experience in the management of culture collections and in the cultivation, preservation, identification and transportation of bacteria. His research and personal interests include taxonomy, microbial biofilms, and probiotics. He has 30 peer-reviewed publications and is currently a member of the Executive Board of the World Federation of Culture Collections (WFCC). Dr Green has presented talks and/or written articles on the use of Coley fluid at several scientific meetings in the UK and overseas, including the L.B.Perry Memorial lecture 2008 at UK Society of Applied Microbiology (SfAM) and as a keynote speaker at the 2010 UK Institute of Biomedical Sciences (IBMS) meeting.

Thomas Ichim, PhD, is chief executive officer of Medistem, a biotechnology company developing technologies related to adult stem cell extraction and manipulation for use in treating inflammatory and degenerative diseases. Dr. Ichim is an immunologist, an expert in clinical research, and has been extensively published in various journals in the fields of cell therapy and immunology. Tom is the founder and CEO of the non-for-profit organization, the Batu Center for Leukemia Research, and was chosen as one of the Top Ten Most Honorable Canadians by Maclean's Magazine in the year 2000 for scientific and humanitarian contributions.

Michael J. Lane, Ph.D. is a professor in the Department of Medicine at the State University of New York-Upstate Medical University in Syracuse. He is the author or co-author of numerous peer-reviewed publications and the inventor or co-inventor of more than 33 published patents. Dr. Lane is the founder of two biotechnology companies: Genmap, Inc., of New Haven, CT, the first commercial human genome enterprise, and Tm Bioscience Corporation, Toronto, Canada, a biochip and genomics company.

Xiang-Dong Lei, Ph.D., is a molecular biologist. As the Director, Research & Development, at a biotechnology company, he oversaw therapeutic cancer vaccine development from antigen discovery through IND filing. Dr. Lei also oversaw the molecular diagnosis program for QIAGEN in China. Dr. Lei is currently the chairman of CT Bioscience. Dr. Lei has published 15 peer-reviewed papers, is the co-inventor on two patent applications, and is a member of the American Association of Cancer Research, the Project Management Institute, and American Society for Quality.

Liping Liu, Ph.D., MBA:  Dr. Liu is the director of R&D at Stealth Peptides Inc. (SPI), a privately held global biopharmaceutical company developing innovative therapies.  Prior to SPI, she held positions as research director at CTL Immunotherapies Corp (merged into MannKind Corp in 2003), senior manager of R&D at MannKind Corporation, and head of the proteomics and biomarker program at American Type Culture Collection (ATCC).  Through her tenure at CTL and MannKind, Dr. Liu has invented and developed multiple peptide candidates for cancer treatment.  Four candidates advanced into clinical trials, and two are currently in Phase II trial. Dr. Liu has 20 years experience in peptide research and development. She has 25 peer-reviewed journal publications, 3 issued patents, and 10 patents pending approval in multiple jurisdictions.  Dr. Liu has a PhD degree in biomolecular chemistry from Nankai University, China; and did her post-doctoral training at University of Toronto/Hospital for Sick Children.  She received her MBA from the Carey Business School of Johns Hopkins University. She is a member of the American Association for Cancer Research (AACR) and the American Peptide Society.

Johannes (Hans) van Netten, Ph.D.  is a visiting scientist in the Department of Biological Sciences, University of Victoria. He has been interested in the relationship of the endocrine as well as the immune system on breast cancer growth. In 1994 his work on the positive effect of macrophages on breast cancer growth was the subject of a press release by The Lancet. Since then, his interest has been to find ways to negate this effect of macrophages on tumor growth. Dr. van Netten has authored or co-authored more than 40 papers dealing with cancer growth regulation.